There are other ongoing clinical trials to further assess AMG510, such as NCT04185883, which will assess the safety and feasibility of various combinational therapies; NCT04303780, which compares AMG510 with docetaxel; and NCT04625647, which will evaluate the response rate of AMG510 in participants with KRAS (G12C)-mutated stage IV or recurrent nonsquamous NSCLC (Table 2). This evidence concerns the gene KRAS and non-small cell lung carcinoma.